for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Akebia Therapeutics Inc

AKBA.OQ

Latest Trade

3.58USD

Change

-0.12(-3.24%)

Volume

1,413,358

Today's Range

3.31

 - 

3.75

52 Week Range

2.35

 - 

13.71

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.70
Open
3.74
Volume
1,413,358
3M AVG Volume
127.39
Today's High
3.75
Today's Low
3.31
52 Week High
13.71
52 Week Low
2.35
Shares Out (MIL)
143.13
Market Cap (MIL)
522.63
Forward P/E
-1.62
Dividend (Yield %)
--

Next Event

Akebia to Present Global Phase 3 Vadadustat Data at American Society of Nephrology Kidney Week 2020 Reimagined

Latest Developments

More

Akebia Therapeutics Says Biovectra, Keryx Entered Into Amended, Restated Product Manufacture Agreement

Akebia Therapeutics Announces Top-Line Results From Its Pro2tect Global Phase 3 Program Of Vadadustat

Akebia Reports Q2 Revenue Of $90.1 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Akebia Therapeutics Inc

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).

Industry

Biotechnology & Drugs

Contact Info

245 1st St

CAMBRIDGE, MA

02142-1200

United States

+1.617.8712098

https://akebia.com/

Executive Leadership

Adrian Adams

Independent Chairman of the Board

John P. Butler

President, Chief Executive Officer, Director

David A. Spellman

Chief Financial Officer, Senior Vice President, Treasurer

Michel Dahan

Chief Operating Officer, Senior Vice President

Nicole R. Hadas

Senior Vice President, Chief Legal Officer, Corporate Secretary

Key Stats

2.25 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.2K

2018

0.2K

2019

0.3K

2020(E)

0.3K
EPS (USD)

2017

-1.770

2018

-1.540

2019

-2.360

2020(E)

-2.331
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.54
Price To Book (MRQ)
1.43
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
20.62
LT Debt To Equity (MRQ)
20.62
Return on Investment (TTM)
-64.95
Return on Equity (TTM)
-49.16

Latest News

Latest News

Akebia plunges 73% after anemia treatment fails to meet safety goal

Akebia Therapeutics Inc said on Thursday its experimental drug failed to meet the main safety goal in a late-stage trial testing the treatment in patients with anemia due to chronic kidney disease and not undergoing dialysis.

Akebia Therapeutics' anemia treatment fails to meet safety goal in late-stage study

Akebia Therapeutics Inc said on Thursday its experimental drug to treat anemia in patients with chronic kidney disease failed to meet the main goal on safety in a late-stage trial.

BRIEF-Akebia Therapeutics Reports Approval Of Vadadustat In Japan

* AKEBIA THERAPEUTICS ANNOUNCES APPROVAL OF VADADUSTAT IN JAPAN FOR THE TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN DIALYSIS-DEPENDENT AND NON-DIALYSIS DEPENDENT ADULT PATIENTS

BRIEF-Akebia Therapeutics Announces David Spellman As Chief Financial Officer

* AKEBIA THERAPEUTICS INC - DAVID SPELLMAN IS JOINING AKEBIA AS ITS NEW SENIOR VICE PRESIDENT, CFO AND TREASURER, EFFECTIVE JUNE 29, 2020

BRIEF-Akebia Therapeutics Announces Data On Different Dosing Regimens Of Ferric Citrate For Iron Deficiency Anemia

* AKEBIA THERAPEUTICS ANNOUNCES DATA ON DIFFERENT DOSING REGIMENS OF FERRIC CITRATE FOR IRON DEFICIENCY ANEMIA PRESENTED AT 57TH ERA-EDTA VIRTUAL CONGRESS Source text for Eikon: Further company coverage:

BRIEF-Akebia Therapeutics Announces Pricing Of Upsized Public Offering Of Common Stock

* AKEBIA THERAPEUTICS ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Akebia Therapeutics Reports Qtrly Loss Per Share Of $0.47

* AKEBIA ANNOUNCED POSITIVE TOP-LINE RESULTS FROM GLOBAL PHASE 3 PROGRAM OF VADADUSTAT FOR TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULT PATIENTS ON DIALYSIS; REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Akebia Announces Positive Top-Line Results From Global Phase 3 Program Of Vadadustat

* AKEBIA THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM GLOBAL PHASE 3 PROGRAM OF VADADUSTAT FOR TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULT PATIENTS ON DIALYSIS

BRIEF-Vifor Pharma: Akebia Reports Positive Top-Line Results From Inno(2)Vate

* VIFOR PHARMA ANNOUNCES AKEBIA’S POSITIVE TOP-LINE RESULTS FROM GLOBAL PHASE-III PROGRAM OF VADADUSTAT FOR TREATMENT OF ANAEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULT DIALYSIS-DEPENDENT PATIENTS

BRIEF-Akebia Therapeutics Enters Supply Agreement With STA Pharma Hong Kong

* ON APRIL 2 ENTERED INTO A SUPPLY AGREEMENT WITH STA PHARMACEUTICAL HONG KONG LIMITED, A SUBSIDIARY OF WUXI APPTEC

BRIEF-Akebia Therapeutics Asked All Office-Based Employees To Work Remotely Due To Coronavirus

* ASKED ALL OFFICE-BASED EMPLOYEES TO WORK REMOTELY DUE TO CORONAVIRUS

BRIEF-Akebia Therapeutics Reports Q4 Revenue $69.6 Mln Versus $59.9 Mln

* AKEBIA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS AND HOSTS CONFERENCE CALL TO DISCUSS RECENT BUSINESS HIGHLIGHTS

Former Akebia employee gets three years in prison for insider trading

A former Akebia Therapeutics Inc employee was sentenced on Monday to three years in prison after being convicted of working with a friend at a rival drugmaker to engage in insider trading based on information they learned about drug studies, according to the office of Massachusetts...

Ex-Akebia employee jailed for night as insider trading trial starts

A former Akebia Therapeutics Inc <AKBA.O> employee accused of engaging in an insider trading scheme must spend a night in jail after he violated a U.S. judge's order and spoke to a witness at the start of his trial on Tuesday.

BRIEF-Akebia Therapeutics Reports Q1 Loss Per Share $0.48

* AKEBIA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Akebia Therapeutics Announces Proposed Public Offering Of Common Stock

* AKEBIA THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Akebia Therapeutics Inc Files For Potential Mixed Shelf Offering Amount Not Disclosed - SEC Filing

* AKEBIA THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; AMOUNT NOT DISCLOSED - SEC FILING Source text (http://bit.ly/2tG5aJJ) Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Akebia Therapeutics Announces Q4 Earnings Per Share $0.25

* AKEBIA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

BRIEF-Akebia Therapeutics Gives Update On Vadadustat Development Program

* AKEBIA THERAPEUTICS PROVIDES UPDATE ON VADADUSTAT DEVELOPMENT PROGRAM

BRIEF-Akebia Therapeutics reports Q3 loss per share $0.49

* Akebia Therapeutics announces third quarter 2017 financial results

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up